Trastorno bipolar

  1. Arrieta, M. 1
  2. Molero Santos, P. 1
  1. 1 Departamento de Psiquiatría y Psicología Médica. Clínica Universidad de Navarra, Pamplona, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2019

Título do exemplar: Enfermedades psiquiátricas (III) Psicosis. Trastornos del humor

Serie: 12

Número: 86

Páxinas: 5052-5066

Tipo: Artigo

DOI: 10.1016/J.MED.2019.09.013 DIALNET GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Obxectivos de Desenvolvemento Sustentable

Resumo

Bipolar disorder (BD) is a serious mental disorder, which affects more than 1% of worldwide population. Is characterized by extreme disturbance in mood alternating depression with mania. It is accompanied by emotional and cognitive disorders, as well as recurrent changes in mood and behavior. Its chronic and recurrent nature leads to functional and cognitive impairment, related with lower quality of life and higher mortality (mainly suicide and heart disease). In spite of appearing at early ages, therapeutic approach begins in adulthood, taking into account the time elapsed since the appearance of the first symptoms and the diagnosis.

Referencias bibliográficas

  • Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804-17.
  • Blanco C, Compton WM, Saha TD, Goldstein BI, Ruan WJ, Huang B. Epidemiology of DSM-5 bipolar I disorder: results from the national epidemiologic survey on alcohol and related conditions - III. J Psychiatr Res. 2017;84:310-7.
  • Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple treatments meta-analysis. Lancet. 2011;378: 1306-15.
  • Clemente AS, Diniz BS, Nicolato R, Kapczinski FP, Soares JC, Firmo JO. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Rev Bras Psiquiatr. 2015;37:155-61.
  • Goodwin F, Jamison K. Manic-depressive illness: bipolar disorders and recurrent depression. Oxford: Oxford University Press; 2007.
  • Craddock N, Sklar P. Genetics of bipolar disorder. Lancet. 2013;381:1654-62.
  • Cullen B, Ward J, Graham NA, Deary IJ, Pell JP, Smith DJ. Prevalence and correlates of cognitive impairment in euthymic adults with bipolar disorder: A systematic review. J Affect Disord. 2016;05:165-81.
  • Dagani J, Signorini G, Nielssen O, Bani M, Pastore A, Girolamo G. Meta-analysis of the interval between the onset and management of bipolar disorder. Can J Psychiatry. 2017;62:247-58.
  • Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008; 20:131-7.
  • Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open label trial. Lancet. 2010;375:385-95.
  • Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387:1561-72.
  • Henriksen TE, Skrede S, Fasmer OB, Schoeyen H, Leskauskaite I, Bjørke-Bertheussen J. Blue blocking glasses as additive treatment for mania: a randomized placebo controlled trial. Bipolar Disord. 2016;18: 221-32.
  • Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA. The long term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530-37.
  • Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD. A prospective investigation of the natural history of the long term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003; 60: 261-9
  • Kaplan HI, Sadock BJ. Sinopsis de psiquiatría. 11ª ed. Madrid: Wolters Kluwer; 2015.
  • Macneil CA, Hasty MK, Berk M, Henry L, Evans M, Redlich C. Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. Early Interv Psychiatry. 2011;5:100-7.
  • Martínez-Aran A, Vieta E. Cognition as a target in schizophrenia, bipolar disorder and depression. Eur Neuropsychopharmacol. 2015;25:151-7.
  • Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M. Lifetime and 12 month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543-52.
  • Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241-51.
  • Michalak EE, Murray G, Young AH, Lam RW. Burden of bipolar depression: impact of disorder and medications on quality of life. CNS Drugs. 2008;22:389-406.
  • Mitchell PB, Malhi GS. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord. 2004;6:530-3.
  • PacchiarottiI, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW. TheInternational Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170:1249-62.
  • Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet. 2013;381:1663-71.
  • Rowland TA, Marwaha T. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 2018;8(9):251-69.
  • Schaffer A, Isometsä ET, Tondo L, Moreno D, Turecki G, Reis C. International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and metaregression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord. 2015;17:1-16.
  • Scott J, Murray G, Henry C, Morken G, Scott E, Angst J. Activation in bipolar disorders a systematic review. JAMA Psychiatry. 2017;74(2):189-96.
  • Stahl SM. Psicofarmacología esencial de Stahl. Guía del Prescripto. 5ª ed. Madrid: Aula Médica; 2015.
  • Taylor D, Barnes T, Young A. The Maudsley prescribing guidelines in psychiatry. 13rd ed. West Sussex: Wiley Blackwell; 2015.
  • Tondo L, Lepri B, Cruz N, Baldessarini RJ. Age at onset in 3014 Sardinian bipolar and major depressive disorder patients. Acta Psychiatr Scand. 2010;121:446-52.
  • Valentí M, Pacchiarotti I, Undurraga J, Bonnín CM, Popovic D, Goikolea JM. Risk factors for rapid cycling in bipolar disorder. Bipolar Disord. 2015;17:549-59.
  • Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15: 166-74.
  • Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR. Nat Rev Dis Primers. 2018;4:18008.
  • Vieta E, Pérrez V. Depresiones bipolares y unipolares. 1ª ed. Madrid: Editorial Panamericana; 2012.
  • Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 2016;3:171-8.
  • Welten CC, Koeter MW, Wohlfarth TD, Storosum JG, van den Brink W, Gispende Wied CC. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. J Clin Psychiatry. 2016;77: 1117-23.
  • Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta-analysis on comparative efficacy and all cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. 2015;45:299-317.
  • Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36:375-89.
Fonte de datos: Dialnet